• Icarus Medical

  Participated · Series A · Jun 2026

  Icarus Medical develops a new class of orthopedic bracing technologies that combine biomechanics, software, and additive manufacturing to address osteoarthritis, post-operative recovery, neurological conditions, and complex lower-extremity mobility challenges. Key products include the Ascender Knee Brace for patellofemoral and multicompartment osteoarthritis and the Adonis Joint Distraction Knee Brace for unicompartmental osteoarthritis. The company designs and manufactures its products in Charlottesville, Virginia, and plans to expand manufacturing capacity as part of its growth strategy. Icarus intends to advance clinical validation of its devices while accelerating commercialization across the U.S. and hiring additional personnel. Its recent recognition includes placement on the Inc. 5000 list for 1,283% three-year growth and the 2026 CBIC Startup of the Year Award.

• Lenoss Medical

  Participated · Equity · Mar 2026

  Lenoss Medical is a growth-stage biomedical company headquartered in Providence, RI, focused on biological solutions for physiological repair of skeletal defects. Its flagship platform, OsteoPearl®, is an implant and surgical instrument system designed to enable physicians to place natural bone where additional bone is required in spinal vertebral augmentation procedures. The company reported record sales in the fourth quarter and year-over-year surgical procedure growth of nearly 150%, demonstrating accelerating clinical adoption. Management plans to use new capital to expand commercial coverage by hiring regional sales leadership, to increase clinical data generation, and to scale operations and marketing to support further adoption. The company is led by an experienced team of MedTech professionals and counts multiple venture investors and angels among its backers.

• Vermeer

  Participated · Series A · Oct 2025

  Headquartered in New York with forward operations in Kyiv, Vermeer builds a Visual Positioning System (VPS) that uses electro-optical or infrared cameras, landmark databases, and AI to give drones precise, GPS-free navigation even when satellite signals are jammed or spoofed. The passive, signal-independent architecture makes the technology attractive for both defense missions and civilian aerial applications such as autonomous vehicles and remote delivery. Vermeer counts more than 30 customers, including the U.S. Army, U.S. Air Force, Lockheed Martin, Northrop Grumman, and the Armed Forces of Ukraine, and its VPS is already deployed on the battlefield in Ukraine. The company emerged from the U.S. Air Force Techstars accelerator, where it secured over $7 million in SBIR and AFWERX non-dilutive awards to refine its technology. Staff has grown from 10 to 40 employees over the past year as demand accelerates. Proceeds from the latest financing will be used to scale product development and deepen partnerships with the U.S. military, NATO allies, and Ukrainian forces. Longer-term, Vermeer aims to make its VPS the standard navigation layer for drones, robots, and other autonomous systems worldwide.

• ClinOne

  Participated · Series A · Nov 2023

  ClinOne offers a single platform that connects, informs, and empowers patients, care partners, and trial sites, supporting trial awareness, consent management, and patient experience/retention. The platform is underpinned by comprehensive data-insights tools and standards-based interoperability to simplify processes. Its solutions are used by more than 80 sponsors, CROs, and site networks across 60 countries and serve therapeutic areas including Oncology, Rare Disease, Pediatrics, the Elderly, and CNS. ClinOne states its solutions are proven to reduce risk and simplify processes for sponsors and sites. The company intends to use newly raised funds to expand operations and its business reach. ClinOne is based in Needham, MA. ClinOne offers a platform for trial and consent management, patient engagement, comprehensive data-insights tools, and interoperability to connect patients, caregivers, and sites in clinical trials. The platform is used by more than 80 sponsors, CROs, and site networks across 60 countries. Its product aims to reduce risk and simplify complex processes across therapeutic areas including oncology, rare disease, pediatrics, the elderly, and CNS. Led by CEO Andrea Valente, ClinOne emphasizes patient and site empowerment through its suite of tools. The company recently completed a $3M Series A to support growth. It intends to use the funds to accelerate platform development and broaden its customer reach. ClinOne operates the ClinOne and ClinTrialConnect platforms to enable pharmaceutical sponsors, research sites and participants to perform and automate recruitment, study execution, compliance and patient retention from any location worldwide. Its modular product suite includes patient recruitment, remote consent (eConsent), patient-reported outcomes and surveys (ePRO), dosing management and remote vital-sign data collection, and it integrates with home healthcare visits and telemedicine video visits. ClinOne conducts clinical trials in 55 countries across 43 languages. The company added the CU Healthcare Innovation Fund as lead investor in a Series-A financing with a first closing of $3.6 million. Management said the funding will be used to expand the product suite and sales efforts to meet high demand. The announcement also referenced a partnership with portfolio company BioIntelliSense to enable more robust remote patient monitoring in clinical trial management.

• Solenic Medical

  Participated · Series A · Jun 2023

  Solenic Medical, based in Addison, TX and led by CEO James Y. Lancaster, develops a device that uses alternating magnetic fields (AMF) generated from external coils to eradicate biofilm on the surface of medical implants. The company's initial product targets the metallic components of knee implants. Its pipeline aims to extend the AMF treatment to most metallic medical implants including hips, elbows and trauma devices. Solenic plans to commercialize this method for treating prosthetic joint infections (PJI). The company raised funding to support expansion of operations and its R&D sector. The articles do not provide operating metrics such as revenue or user counts.

No current team members are available.